Table of Contents

Exhibit 99.36

ISOTECHNIKA PHARMA INC.

NOTICE OF ANNUAL & SPECIAL MEETING

OF SHAREHOLDERS

TO BE HELD ON

August 15, 2013

and

MANAGEMENT INFORMATION CIRCULAR

Dated July 19, 2013

Table of Contents

ISOTECHNIKA PHARMA INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

NOTICE is hereby given that the Annual and Special Meeting (the “Meeting”) of Shareholders of Isotechnika Pharma Inc. (the “Company”) will be held at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, British Columbia on August 15, 2013, at 2:00 PM, Pacific Time, for the following purposes:

Table of Contents

Management of the Company is soliciting proxies on the accompanying form of proxy. Shareholders who are unable to attend the Meeting are requested to complete, date, sign and return the enclosed form of proxy so that as large a representation of shareholders as possible may be had at the Meeting. Specific details of the matters being put before the Meeting, in particular with respect to the election of the directors nominated by Management, are set forth in more detail in the accompanying Management Information Circular.

A copy of the Management Information Circular, a Supplemental Mailing List Reply Form, a form of proxy and a return envelope accompany this Notice of Meeting.

The Board of Directors (the “Board”) has determined that only holders of record of the Common Shares at the close of business on June 26, 2013 will be entitled to vote in respect of the items set out in this Notice of Meeting at the Meeting. The Board has also determined that 2:00 PM, Pacific Time, on August 13, 2013 as the time before which proxies to be used or acted upon at the Meeting or any adjournment thereof shall be deposited with the Company’s transfer agent. Failure to properly complete or deposit a proxy may result in its invalidation.

DATED at Edmonton, Alberta, Canada, July 19, 2013.

Table of Contents

Table of Contents

APPENDIX “A” – STATEMENT OF CORPORATE GOVERNANCE PRACTICES

APPENDIX “B” – MANDATE OF THE BOARD OF DIRECTORS

APPENDIX “C” – PROPOSED TEXT OF RESOLUTIONS

APPENDIX “D” – FAIRNESS OPINION

APPENDIX “E” – AURINIA FINANCIAL STATEMENTS

APPENDIX “F” – PRO FORMA FINANCIAL STATEMENTS

APPENDIX “G” – GLOSSARY

1

Table of Contents

MANAGEMENT INFORMATION CIRCULAR

FORWARD-LOOKING STATEMENTS

This Information Circular contains forward looking statements that are based on beliefs of the management of Isotechnika Pharma Inc. (the “Company”) as well as assumptions made by and information currently available to the Company. When used in this Information Circular, the words “estimate”, “project”, “believe”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may”, “should”, “will”, the negative thereof or other variations thereon or comparable terminology are intended to identify forward looking statements.

Forward-looking information in this Information Circular includes, but is not limited to:

Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable. Assumptions have been made regarding, among other things: the ability to create synergies between the Company and Aurinia Pharmaceuticals Inc. (“Aurinia”), the timely receipt of required approvals, the Company’s ability to operate in an efficient and effective manner and the Company’s ability to obtain financing as and when required and on reasonable terms. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used.

By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond the control of the Company that could influence actual results include, but are not limited to: the failure to consummate the Arrangement, First Unit Offering or Second Unit Offering, operating losses and future capital needs, reliance on short term financing, risks associated with the Company’s evolving business model, development and acceptance of new products, managing growth, dependence on key personnel, dependence on key customers and suppliers, infringing intellectual property rights of third parties, dependence on intellectual property, dependence on third party manufacturers, design defects, errors or “bugs”, competition, price volatility of public stock, control of significant shareholders, conflicts of interest, dividends, compliance with government regulation, tax risks, geopolitical risks, and other factors beyond the control of the Company.

Our forward-looking statements are based on the reasonable beliefs, expectations and opinions of management on the date of this Information Circular. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except as, and to the extent required by, applicable securities laws.

2

Table of Contents

PART 1

VOTING INFORMATION

This information circular is furnished in connection with the solicitation by the management of the Company of proxies to be voted at the Annual and Special Meeting of Shareholders of the Company (the “Meeting”), to be held at 1200 Waterfront Centre, 200 Burrard Street, Vancouver, British Columbia, on August 15, 2013, at 2:00 PM, Pacific Time, for the purposes set forth in the accompanying Notice of Meeting, and at any adjournment thereof. Except as otherwise stated, the information contained herein is given as at June 26, 2013, and all dollar amounts and references to $ or to CDN$ are to Canadian dollars, unless otherwise indicated.

The enclosed proxy is being solicited by the management of the Company and the expenses of solicitation of proxies will be borne by the Company. The solicitation will be made primarily by mail; however, officers and regular employees of the Company may also solicit proxies by telephone, telecopier, electronic mail or in person.

The persons named in the enclosed form of proxy are directors or officers of the Company. Each shareholder is entitled to appoint any other person to represent him at the Meeting, and at any adjournment thereof.

A shareholder desiring to appoint another person (who need not be a shareholder) to represent him at the Meeting, and at any adjournment thereof, may do so either by striking out the names of the management nominees set forth in the form of proxy and inserting such person’s name therein or by completing another proper form of proxy and, in either case, sending the completed proxy in the enclosed reply envelope for delivery before the Meeting, or any adjournment thereof, or by depositing such proxy with the Chairman on the day of the Meeting, at the Meeting or any adjournment thereof.

A shareholder giving a proxy pursuant to this solicitation may revoke any such proxy by an instrument in writing executed by the shareholder or by his attorney duly authorized in writing, or if the shareholder is a corporation, executed under its corporate seal or by an officer or attorney duly authorized in writing, and deposited with the Company, c/o Computershare Investor Services Inc., Attention: Proxy Department, 100 University Avenue, 9^th Floor, North Tower, Toronto, Ontario M5J 2Y1, at any time up to and including the close of business two business days preceding the day of the Meeting, or any adjournment thereof, or with the Chairman on the day of the Meeting, at the Meeting or any adjournment thereof, before any vote is cast under the proxy’s authority.

Holders of common shares of the Company (the “Common Shares”) listed as shareholders at the close of business on June 26, 2013 will be entitled to vote at the Meeting, or any adjournment thereof, either in person or by proxy, in respect of all matters which may properly come before the Meeting, or any adjournment thereof.

The names of the shareholders whose shares are held in the name of a broker or another intermediary will not appear on the list of shareholders of the Company. If you are not a registered shareholder of the Company, in order to vote you must a) obtain the material relating to the Meeting from your broker or other intermediary; b) complete the request for voting instructions sent to you by the broker or other intermediary; and c) follow the directions of the broker or other intermediary with respect to voting procedures.

In accordance with National Instrument 54-101 adopted by the Canadian Securities Administrators (the “CSA”) entitled “Communications with Beneficial Owners of Securities of a Reporting Issuer” (“NI 54-101”), the Company is distributing copies of the material related to the Meeting to clearing agencies and intermediaries for distribution to non-registered holders. Such agencies and intermediaries must forward the material related to the Meeting to non-registered holders and often use a service company (such as Broadridge Financial Solutions in Canada) to permit you, if you are not a registered shareholder, to direct the voting of the Common Shares which you beneficially own. If you are a non-registered shareholder of the Company, you may revoke voting instructions which have been given to an intermediary at any time by written notice to the intermediary. If you are a non-registered shareholder of the Company, you should submit your voting instructions to your intermediary or broker in sufficient time to ensure that your votes are received, from your intermediary or broker, by Computershare Investor Services Inc. on behalf of the Company, as set forth under the heading “Appointment and Revocation of Proxies”.

Management of the Company does not intend to pay for intermediaries to forward the meeting materials to objecting beneficial owners under NI 54-101 and any such objecting beneficial holder will not receive the meeting materials unless the objecting beneficial holder’s intermediary assumes the cost of delivery.

3

Table of Contents

The Company is organized pursuant to the provisions of the Business Corporations Act (Alberta) (the “ABCA”).

The persons named in the enclosed form of proxy will vote or withhold from voting the Common Shares in respect of which they are appointed in accordance with the directions of the shareholders appointing them.

In the absence of such directions, such Common Shares will be voted:

All matters to be voted upon at the Meeting will be decided by a majority of the votes cast by the shareholders entitled to vote thereon, other than the resolution to approve the amendments to the constating documents of the Company and the resolution to approve the share consolidation, which will each require a special majority of 66 2/3% of the votes cast at the Meeting in order to be approved. In addition, the Share Issuance Resolution will require the approval of a majority of the shareholders of the Company, other than ILJIN, for what is referred to as a majority-of-the-minority vote.

The enclosed form of proxy confers discretionary authority upon the persons named therein with respect to amendments or variations to matters identified in the accompanying Notice of the Meeting or with respect to such other matters as may properly come before the Meeting, or any adjournment thereof. At the date hereof, management of the Company knows of no such amendments, variations or other matters to be presented for action at the Meeting, or any adjournment thereof. However, if any other matters which are not now known to management should properly come before the Meeting, or any adjournment thereof, the persons named in the enclosed form of proxy will vote on such matters in accordance with their best judgment.

The Company is authorized to issue an unlimited number of Common Shares without nominal or par value. As at June 26, 2013 there were 215,526,804 Common Shares issued and outstanding as fully paid and non-assessable, each carrying the right to one vote per Common Share. To the knowledge of the directors and officers of the Company, as at June 26, 2013, no person beneficially owned, directly or indirectly, or exercised control or direction over, shares of the Company carrying 10% or more of the voting rights attached to all outstanding voting shares of the Company, except as follows:

4

Table of Contents

PART 2

BUSINESS OF THE MEETING

The term of office of each of the present directors expires at the Meeting. The persons named below will be presented for election at the Meeting as management’s nominees. The board of directors of the Company (the “Board”) recommends that shareholders vote for the election of the nominees whose names are set forth below. The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the election of the nominees whose names are set forth below unless otherwise directed by the shareholders appointing them.

Management does not contemplate that any of the nominees will be unable to serve as a director, but, if that should occur for any reason at or prior to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee at their discretion, unless instructions have been received from a particular shareholder to withhold its shares from voting with respect to the election of directors. Each director elected will hold office until the earlier of: (i) the closing of the Arrangement; and (ii) the next annual meeting of shareholders or until his successor is duly elected, unless his office is earlier vacated in accordance with the Bylaws of the Company. All of the four (4) persons named in the table below are now members of the Board and have been during the period indicated.

The following table states the names of all of the persons proposed by management to be nominated for election as directors, their municipality, province or state and country of residence, their age, their principal occupation, their position in the Company (if any), the period during which each proposed nominee has served as a director and the number of Common Shares beneficially owned, directly or indirectly, by each of them or over which they exercise control or direction.

5

Table of Contents

Notes:

The following are brief biographies for each of the persons proposed by management to be nominated for election as directors:

Peter Wijngaard, Ph.D., Chairman of the Board

Dr. Peter Wijngaard is the Vice President, Innovation Leader Research & Development for The Medicines Company (Schweiz) GmbH. Prior to this he served as the Senior Director Medical Affairs at ViroPharma Incorporated, and as the Global Alliance Director, Life Cycle Leader in Transplantation, International Medical Manager in Transplantation, and Country Medical Manager Transplantation at Hoffmann-La Roche. He brings extensive experience in the areas of Global Project Leadership, Business Development, Medical Affairs, and Pharmaceutical Marketing. Dr. Wijngaard has a B.Sc. in Clinical Chemistry, and his PhD in Transplantation Immunology from Utrecht University examining the immunological aspects of human heart transplantation. He conducted his Postdoctoral Fellowships at Pharmacia Diagnostics, Inselspital Bern, and Sandoz. He has published extensively in the area of transplant immunology and immunosuppression, with emphasis on the use of mycophenolate mofetil (CellCept ®). From 2005 to 2008, Dr. Wijngaard was a member of the Board of Trustees of the Roche Organ Transplant Research Foundation, which supports important and innovative clinically oriented research projects in organ transplantation. During his tenure, the Foundation managed a total of 67.5 million Swiss Francs donated by F. Hoffmann-La Roche Ltd.

Robert T. Foster, B.Sc. (Pharm.), M.Pharm, Ph.D., President and Chief Executive Officer

Dr. Foster founded the Company and has been an officer and director of the Company since 1993. Dr. Foster was an Associate Professor (clinical pharmacokinetics) in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta until December 1997. From 1990 to 1994, Dr. Foster was Medical Staff, Scientific and Research Associate in the Department of Laboratory Medicine at the Walter C. MacKenzie Health Sciences Centre. He has published approximately 150 papers and abstracts focused on drug analysis and development. Dr. Foster has received numerous awards for both pharmaceutical research and teaching. Dr. Foster has served on the Alberta Science and Research Authority Technology Commercialization Task Force, was a member of the Board of Management for the Alberta Research and Science Authority, has served as Division Chairman of Pharmacy Practice at the University of Alberta and has acted as a consultant with many pharmaceutical companies. He also served as a board member of BioAlberta, on the Alberta Premier’s Advisory Council on Health, and as a member of the Board of Management of the Alberta Economic Development Authority. Dr. Foster is named as an inventor on a total of 242 patents, of which 216 are currently active and granted, 5 additional patents have been allowed and 21 remaining patents that are pending.

Prakash Gowd, B.Sc. (Pharm), MBA

Prakash Gowd has extensive experience in the healthcare and investment fields attained over the last 20 years. He is currently CEO of InDanio Bioscience, a drug discovery and development company with a novel screening platform focused on molecules that target nuclear receptors. He is also President of Gowdra Capital, a life sciences management consulting and investment analysis firm. Mr. Gowd spent eight years as a respected Healthcare Equity Research Analyst with an exemplary track record at National Bank Financial and Canaccord Capital. As an investment professional, he conducted comprehensive company and industry analysis in the biotech, drug development, medical device, and pharmaceutical sectors, then communicated investment recommendations to institutional and retail clients in North America and Europe, and assisted in financing numerous life sciences companies. His experience in the capital markets is balanced by a strong foundation in the pharmaceutical industry, where Mr. Gowd specialized at GSK in market research, marketing and new product development. His consulting work has helped pharma and health sciences companies design, execute and evaluate their drug development and marketing initiatives. Prakash Gowd holds an MBA from McGill University, and a Pharmacy degree from the University of British Columbia.

Donald W. Wyatt, B.S., M.I.P., J.D.

Donald Wyatt has over 20 years of experience in the pharmaceutical industry, including research and legal representation. He has worked in research in large pharmaceutical companies, as an attorney in a law firm, and as in-house patent and general legal counsel. Mr. Wyatt is founder of The Wyatt Group, a consulting firm serving companies worldwide in strategic transactions, relationships and intellectual property strategies. Donald Wyatt was appointed to the Board on December 7, 2011 as the nominee of 3SBio, Inc. (“3SBio”) pursuant to the terms of a Development, Distribution and License Agreement among the Company and 3SBio dated August 6, 2010.

6

Table of Contents

To the knowledge of the directors and officers of the Company, no proposed director of the Company:

The following table sets forth the number of meetings held by the Board and each of its Committees during the fiscal year ended December 31, 2012, and the attendance of each director (in the case of Committees of the Board, the attendance of each member of such Committees) at those meetings.

7

Table of Contents

Note:

In respect of the fiscal year ended December 31, 2012, none of the directors of the Company acted as directors for other reporting issuers.

The Company provides insurance for the benefit of its directors and officers against liability incurred by them in these capacities. The current aggregate policy limit is $5,000,000 (2012 - $10,000,000), the first $250,000 of certain claims being deductible and payable by the Company. The premium is $37,500 for the twelve-month term ending December 31, 2013 ($56,000 for the twelve-month term ending December 31, 2012). This premium, which has not been specifically allocated between directors as a group and officers as a group, was paid entirely by the Company. The Company has also entered into indemnity agreements with the directors and officers of the Company to provide certain indemnification to such directors and senior officers.

The audited consolidated financial statements of the Company, the report of the auditors thereon, and management’s discussion and analysis thereof for the financial year ended December 31, 2012 will be tabled at the Meeting, but the approval of the shareholders in respect thereto is not required.

The Board recommends that shareholders vote for the appointment of PricewaterhouseCoopers LLP, Chartered Accountants, as auditors of the Company and the authorization of the Audit Committee to fix the auditors’ remuneration. The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the reappointment of PricewaterhouseCoopers LLP, Chartered Accountants, as auditors of the Company for the term expiring with the next annual meeting of shareholders, and to authorize the Audit Committee to fix their remuneration, unless otherwise directed by the shareholders appointing them. PricewaterhouseCoopers LLP were the auditors for the predecessor corporation, Isotechnika Inc., since 1996 and became the auditors for the Company on June 18, 2009.

The aggregate fees recorded for professional services rendered by PricewaterhouseCoopers LLP for the Company for the years ended December 31, 2012 and 2011, respectively, are as follows:

Notes:

The Company has recently found itself in a difficult financial position, and accordingly has recently undergone substantial efforts to secure financing to fund its ongoing operations, as well as to consolidate its business structure within one entity. The results of those efforts are described in this information circular, and involve multiple steps, including: (i) a private placement of units

8

Table of Contents

(each, a “First Unit”, comprised of one Common Share and one common share purchase warrant (a “First Offering Warrant”)) (the “First Unit Offering”) (described below); (ii) a private placement of units (each a “Second Unit”), comprised of one Share and one-half of a common share purchase warrant (the “Second Offering Warrant”) (the “Second Unit Offering”) (described under “The Second Unit Offering”); and (iii) the Arrangement (described under “The Share Issuance Resolution”). Each whole First Offering Warrant is exercisable five years from the date of issuance to obtain one Common Share for $0.05, while each whole Second Offering Warrant is exercisable three years from the date of issuance to obtain one Common Share for $0.05.

The Company will use the proceeds from these financings for its general corporate purposes, including funding outstanding obligations, and ongoing research and development of voclosporin for the lupus nephritis indication (see further under “The Share Issuance Resolution – Reasons for the Arrangement”).

As a result of the rules and policies of the Toronto Stock Exchange, shareholder approval is required, in one aspect or another, for each of these steps. The Company has engaged Canaccord Genuity Corp. (the “Agent”), on a commercially reasonable efforts basis, to assist in it completing the First Unit Offering and the Second Unit Offering, including through the sale of the securities comprising such offerings.

Management of the Company is of the opinion that if the First Unit Offering and the Second Unit Offering are not approved and completed, as applicable, the ability of the Company to continue operating as a going concern will be in jeopardy. Each of the above-mentioned steps is considered vital to the ongoing business and operations of the Company. Management of the Company and the Board therefore recommend that shareholders vote in favour of the First Offering Approval Resolution, the Second Offering Approval Resolution and the Share Issuance Resolution to give effect to these steps.

A step-by-step table setting out the maximum securities issuable in each step of the financing structure is set out below.

Following the First Unit Offering, the Arrangement and the Second Unit Offering, and assuming the maximum number of shares issuable in each transaction are issued as a whole and to ILJIN, it is anticipated that ILJIN will hold up to 187,141,594 Common Shares, representing approximately 27.93% of the issued and outstanding Common Shares on a non-diluted basis, and ILJIN will also hold an additional 4,444,444 First Offering Warrants and up to 22,222,222 Second Offering Warrants, or, in the aggregate, up to 25.80% of the issued and outstanding Common Shares on a fully-diluted basis. ILJIN’s described holdings of the Company are comprised of 24,000,000 Common Shares held prior to June 25, 2013, 4,444,444 First Units (comprised of 4,444,444 Common Shares and 4,444,444 First Offering Warrants), up to 44,444,444 Second Units (comprised of 44,444,444 Common Shares and 22,222,222 Second Offering Warrants) and 114,252,706 Common Shares being issued pursuant to the Arrangement. It is the intention of the Company and ILJIN that ILJIN will hold 25% of the Common Shares on a fully-diluted basis upon completion of the First Unit Offering, the Arrangement and the Second Unit Offering. On a step-by-step basis:

9

Table of Contents

and, in sum, in connection with the First Unit Offering, the Arrangement, and the Second Unit Offering, ILJIN would be issued up to 189,808,261 Common Shares (assuming exercise of the First Offering Warrants and Second Offering Warrants), which in the aggregate represent 98.4% of the issued and outstanding Common Shares as of June 25, 2013. Combined with its holdings as of June 25, 2013, this would represent an aggregate of 213,808,261 Common Shares, or 110.9% of the issued and outstanding Common Shares as of June 25, 2013.

Based on the same assumptions as in the previous paragraph, there will be no other holders of greater than 10% of the issued and outstanding Common Shares following the First Unit Offering, the Arrangement and the Second Unit Offering and the directors and officers of the combined entity will hold, as a group, less than 13% of the then issued Common Shares, with Richard Glickman holding approximately 5.49%, Michael Martin holding approximately 4.83% and Robert Foster holding approximately 0.95%, on a non-diluted basis.

The first of these matters is the First Unit Offering, pursuant to which up to a maximum of 44,445,000 First Units may be issued in one or more closings on the basis of $0.045 per First Unit. Each First Unit is comprised of one Common Share and one First Offering Warrant, with each First Offering Warrant exercisable for one Common Share at a price of $0.05 per Common Share for a period of five years from their respective date of issuance. If all First Offering Warrants were exercised, a total of 44,445,000 additional Common Shares would be issued. If all First Units were issued, they would represent 23.04% of the Company’s issued and outstanding Common Shares as of June 25, 2013, or 27.84% on a fully-diluted basis. The First Unit Offering had a first closing on June 26, 2013, and 22,655,555 First Units were sold at that time. As the aggregate number of Common Shares available to be issued in the First Unit Offering, being 44,445,000, is less than 25% of the Company’s issued and outstanding Common Shares immediately prior to the closing of the First Unit Offering, shareholder approval is not being sought for the issuance of the Common Shares in the First Unit Offering. However, the rules and policies of the TSX required that shareholder approval be obtained for the issuance of the First Offering Warrants and the securities underlying the First Offering Warrants in connection with the First Unit Offering, as the total number of securities to be issued in the First Unit Offering is greater than 25% of the Company’s issued and outstanding Common Shares immediately prior to the First Unit Offering. Accordingly, the First Offering Warrants are not exercisable until shareholder approval has been obtained. If approval of the shareholders of the Company is not obtained by September 15, 2013, the First Offering Warrants will automatically expire.

ILJIN, an insider of the Company, and Dr. Richard Glickman a director and shareholder of Aurinia, participated in the First Unit Offering by cancelling their respective promissory notes issued by the Company in the amount of $200,000 each. Each of ILJIN and Dr. Glickman was issued 4,444,444 First Units from the First Unit Offering, each comprised of 4,444,444 Common Shares and 4,444,444 First Offering Warrants. ILJIN currently holds 28,444,444 Common Shares (13.20% on a non-diluted basis) and 4,444,444 First Offering Warrants (12.00% of the Common Shares on a fully diluted basis). Dr. Glickman holds 4,444,444 Common Shares (2.06% on a non-diluted basis) and 4,444,444 First Offering Warrants (3.24% of the Common Shares on a fully-diluted basis).

The Company is seeking the approval of the shareholders of the Company for the issuance of the First Offering Warrants in the First Unit Offering, as well as the securities underlying such First Offering Warrants.

In connection with the First Unit Offering, the Company agreed to pay the Agent a cash commission of 7% of the gross proceeds from the First Unit Offering and common share purchase warrants (“Broker Warrants”) equal to 7% of the First Units sold. Each Broker Warrant issued in the First Unit Offering is exercisable five years from the date of issuance to obtain one Share for $0.045. In connection with the first closing of the First Unit Offering, the Company issued 936,666 Broker Warrants to the Agent. The subscription by ILJIN and Dr. Glickman were not included in the First Units on which the commission or Broker Warrants were payable. If all the First Units were issued, a total of 2,488,928 Broker Warrants would be issued (including the 936,666 Broker Warrants currently issued).

There will not be a material effect on control of the Company as a result of the First Unit Offering.

10

Table of Contents

The First Unit Offering is for gross proceeds of up to $2,000,025. The Company will use the proceeds from the First Unit Offering to repay certain of its accounts payable, for matters in connection with the Arrangement, and for general corporate purposes. Completion of the First Unit Offering is not subject to the completion of any other transaction described in this Information Circular.

The Board recommends that shareholders vote in favour of the approval of the issuance of the First Offering Warrants and the securities underlying such First Offering Warrants. Any Shares issued pursuant to the First Unit Offering will not be permitted to be voted on the First Offering Approval Resolution. The full text of the proposed form of First Offering Approval Resolution is set out in Appendix C hereto.

The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the approval of the First Offering Approval Resolution, unless otherwise directed by the shareholders appointing them.

While the Company believes that the First Unit Offering described above will provide the Company with sufficient funding to continue its business in the ordinary course for a limited period of time following the closing of the Arrangement, management is of the view that additional funding will be required to fund the Company’s operations on a go-forward basis. Accordingly, the Company is proposing to conduct the Second Unit Offering as an additional step of the financing process described in “The First Unit Offering – The Financing Structure”. The timing for the closing of the Second Unit Offering has not been specified, and while it is intended to close following the completion of the Arrangement, it may take place before or after the Share Consolidation described below. Accordingly, the exact number of shares to be issued may vary but the aggregate proceeds and percentage ownership will remain constant.

The Second Unit Offering will be comprised of up to 133,333,332 Second Units. Each Second Unit will be sold for $0.045, meaning that the Company will receive gross proceeds of up to $6,000,000. Each Second Unit is comprised of one Common Share and one-half of a whole Second Offering Warrant. Each whole Second Offering Warrant is exercisable three years from the date of issuance to obtain one Common Share for $0.05. If all Second Offering Warrants were exercised, a total of 66,666,666 additional Common Shares would be issued. As the number of Common Shares issuable pursuant to the Arrangement cannot be finally determined at this time, it is not possible to provide the exact proportion of the Company’s Common Shares that would be represented by the Second Units. However, the maximum issuable Second Units represent 69.13% of the Company’s Common Shares on a non-diluted basis and 87.75% of the Company’s Common Shares on a fully-diluted basis as of June 25, 2013.

It is intended that ILJIN will participate in the Second Unit Offering for up to a maximum of 44,444,444 Second Units (or $2,000,000), representing 44,444,444 Common Shares and 22,222,222 Second Offering Warrants. ILJIN’s participation in the Second Unit Offering would be solely to maintain a minimum of a 25% interest in the Corporation following the completion of the Second Unit Offering. In the last six months, ILJIN was previously issued 4,444,444 First Units in the closing of the first tranche of the First Unit Offering on June 26, 2013, and currently holds 28,444,444 Common Shares (13.20% on a non-diluted basis) and 4,444,444 First Offering Warrants (12.00% of the Common Shares on a fully diluted basis). ILJIN’s maximum allowable Common Share participation in the Second Unit Offering would represent 23.04% of the Company’s Common Shares on June 25, 2013 (the day immediately before the closing of the first tranche of the First Unit Offering), and an additional 11.52% with respect to the Common Shares issuable upon the due exercise of the Second Offering Warrants. Due to its status as an insider of the Company and the level of anticipated participation in the Second Unit Offering, the rules of the TSX will not permit ILJIN to vote any of its securities with respect to the Second Offering Approval Resolution.

The Company will use the proceeds from the Second Unit Offering for its general corporate purposes, including funding outstanding obligations, and ongoing research and development of voclosporin for the lupus nephritis indication (see further under “The Share Issuance Resolution – Reasons for the Arrangement”).

For its services in connection with the Second Unit Offering, the Company will pay a cash commission of 7% and will issue to the Agent up to 9,333,333 Broker Warrants (with each Broker Warrant issued in the Second Unit Offering being exercisable three years from the date of issuance), representing 7% of the maximum number of Second Units issuable in the Second Unit Offering. Each Broker Warrant issued in the Second Unit Offering is exercisable three years from the date of issuance to obtain one Share for $0.045.

The Company is seeking shareholder approval for the issuance of the Second Units issued to subscribers and the securities underlying the Second Units pursuant to the requirements of the TSX to obtain shareholder approval for a private placement where greater than 25% of an issuer’s issued and outstanding common shares are to be issued., and where an insider is being issued greater than 10% of an issuer’s outstanding securities

11

Table of Contents

The Second Unit Offering is subject to approval from the shareholders of the Company at the Meeting and to applicable regulatory approval. There can be no guarantee that the requisite regulatory approvals will be obtained for the Company to be able to proceed with the Second Unit Offering. Completion of the Second Unit Offering is not conditional upon the closing of any other transaction described in this Information Circular; however, if the Arrangement is not approved, the Company does not anticipate that it will be in a position to proceed with the Second Unit Offering.

The Board recommends that shareholders vote in favour of the approval of the issuance of the Second Units, the securities comprising such Second Units, and the Second Units issued to the Agent as a corporate finance fee. The full text of the proposed form of Second Offering Approval Resolution is set out in Appendix C hereto.

The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the approval of the Second Offering Approval Resolution, unless otherwise directed by the shareholders appointing them.

At the Meeting, shareholders of the Company will be asked to consider and, if deemed advisable, to pass the Share Issuance Resolution, substantially in the form set out in Appendix C to this Information Circular.

Background to the Arrangement

The Arrangement Agreement is not yet finalized, but is expected to be completed on substantially the terms described in this information circular. If any material changes are made to the Arrangement Agreement, the Company will issue a press release describing such changes in advance of the Meeting.

12

Table of Contents

The Arrangement

The Arrangement is intended to implement the terms of the Settlement Agreement. In accordance with the terms of the Settlement Agreement, the Company will issue such number of Shares to ILJIN from treasury such that upon completion of the Arrangement ILJIN will hold approximately 25% of the issued and outstanding Shares, on a fully diluted basis.

ILJIN is receiving this level of ownership in the Company in exchange for:

(i) returning to the Corporation and terminating:

(ii) suspending all of its current or contemplated legal or financial claims against the Corporation, Aurinia or Vifor.

The Company will then acquire all of the issued and outstanding common shares in the capital of Aurinia (“Aurinia Shares”) at a ratio of Shares for each Aurinia Share held by an Aurinia shareholder such that following the Arrangement the Shares will be owned 35:65 by former Aurinia shareholders and shareholders of the Company (including ILJIN) respectively. The exact number of Common shares to be issued and issuable pursuant to the Arrangement cannot be determined as of the date of this Circular, as the terms of the Arrangement Agreement are that ILJIN is to hold approximately 25% of the Common Shares following the Arrangement and the Second Unit Offering, while the shareholders of Aurinia are to hold approximately 35% of the Common Shares following the Arrangement and the Company’s current shareholders are to hold approximately 40% of the Common Shares of the Company, all calculated on a on a fully-diluted basis; however, the maximum number of Shares that management of the Company expects to be issued and issuable pursuant to the Arrangement, and the number of Common Shares that shareholder approval is being sought in respect of, is 300,000,000. This represents 155.54% of the issued and outstanding Common Shares as of June 25, 2013. As of the Record Date, there were 215,526,804 Common Shares outstanding and entitled to vote at the Meeting. For a detailed description of the steps involved in the Arrangement, see below under “The Share Issuance Resolution – Steps in the Plan of Arrangement”. As the Arrangement will result in ILJIN holding greater than 20% of the Common Shares, there will be a material effect on the control of the Corporation following the Arrangement.

As a result of the issuance of Common Shares in connection with the Arrangement, the ownership and voting interests of the Company’s current shareholders will be diluted relative to their current proportional ownership and voting interest in the Company.

Pursuant to the rules of the TSX, a listed company is generally required to obtain shareholder approval in connection with an acquisition transaction where the number of securities issued or issuable in payment of the purchase price for the acquisition exceeds 25% of the number of securities of the listed issuer which are outstanding, on a non-diluted basis, prior to the date of closing of the transaction. In addition, shareholder approval is required where greater than 10% of an issuer’s securities are being distributed to an insider in connection with a transaction, and where a transaction could result in a material change on the control of the issuer.

As the Arrangement will result in the Company issuing in excess of 25% of the outstanding Shares, more than 10% of the Company’s Common Shares will be issued to an Insider (ILJIN), and the Arrangement could result in a material change in the control of Isotechnika (through ILJIN acquiring greater than 20% of the Company’s Common Shares), approval of the Share Issuance Resolution by the Company’s shareholders is required. It is a condition of the merger with Aurinia that the Share Issuance Resolution be approved by a simple majority (50% plus one vote) of votes cast at the Meeting by the Company’s shareholders, present in person or by proxy. In addition, as ILJIN is a related party of the Company, the Share Issuance Resolution must be approved by a majority of the votes cast by the Company’s shareholders, other than ILJIN.

The TSX has determined that the Transaction constitutes a backdoor listing and, as a result, the Company must meet the TSX’s original listing requirements upon completion of the Transaction to remain listed on the TSX. The TSX has notified the Company that it does not believe the Company will meet the TSX’s original listing requirements following the completion of the Transaction and, accordingly, will take steps to delist the Company following the completion of the Transaction. The Company anticipates applying to the TSX Venture Exchange to list the Common Shares on such

13

Table of Contents

exchange following the completion of the Transaction, and has had initial discussions to initiate this process. The Company intends to maintain a constant listing for the Common Shares without a period where the Common Shares are not listed on an exchange; however, there can be no assurance that the Company will be successful in achieving this goal.

The Board recommends that shareholders vote in favour of the Share Issuance Resolution. The full text of the proposed form of Share Issuance Resolution is set out in Appendix C hereto.

The Company has prepared unaudited pro forma financial statements as at March 31, 2013, giving effect to the Arrangement. These unaudited pro forma financial statements are included as Appendix F.

Completion of the Arrangement is not subject to the completion of any other matter described in this Information Circular.

Reasons for the Arrangement

In the course of its evaluation of the Arrangement, the Board consulted with the Company’s senior management, legal counsel and financial advisors, reviewed a significant amount of information and considered a number of factors, including, among others, the following:

In reaching their conclusion and making their recommendations, the Board relied on the information provided by the Company’s management and on the advice of its legal and financial advisors. The Board considered numerous other factors to be in favour of the Arrangement including, among others, the following:

14

Table of Contents

A number of these anticipated benefits and factors are based on various assumptions and are subject to various risks. See the sections of this Circular entitled “Forward-Looking Statements and Information” and “The Share Issuance Resolution – Risks Associated with the Arrangement”.

The Board also considered potential adverse factors associated with the Arrangement including, among others, the following:

The foregoing summary of the information and factors considered by the Board is not, and is not intended to be, exhaustive. In view of the wide variety of factors and the amount of information considered in connection with its evaluation of the Arrangement, the Board did not find it practicable to, and did not, quantify or otherwise attempt to assign any relative weight to each specific factor considered in reaching their conclusions and recommendations. In addition, individual directors of the Company may have assigned different weights to different factors.

Fairness Opinion

The Board engaged Evans to provide an opinion to the Board as to the fairness, from a financial point of view, to the Company of the Arrangement Consideration to be paid by the Company in the Arrangement.

Evans provided the Board with a written opinion to the effect that, based upon and subject to the various assumptions, limitations and qualifications contained in its written opinion, the Arrangement Consideration to be paid by the Company in the Arrangement was fair, from a financial point of view, to the Company. The Fairness Opinion does not address any other aspect of the Arrangement and no opinion or view was expressed as to the Arrangement, the relative merits of the Arrangement in comparison to any other strategies or transactions that might be available to the Company or in which the Company might engage or as to the underlying business decision of the Company to proceed with or effect the Arrangement.

The full text of the Fairness Opinion, which sets forth, among other things, the assumptions made, information reviewed and matters considered, and limitations and qualifications on the review undertaken in connection with the opinion, is attached to this Circular as Appendix D. The Fairness Opinion is not intended to be and does not constitute a recommendation to any shareholder as to how to vote or act in connection with the Arrangement or otherwise. The Fairness Opinion was only one of a number of

15

Table of Contents

factors taken into consideration by the Board in considering the Arrangement and should not be viewed as determinative of the views of the Board with respect to the Arrangement or the Arrangement Consideration to be paid by the Company in the Arrangement. This summary of the Fairness Opinion is qualified in its entirety by reference to the full text of the Fairness Opinion and the shareholders are urged to read the Fairness Opinion carefully and in its entirety.

The Fairness Opinion was rendered on the basis of securities markets, economic, monetary, general business, financial and other conditions and circumstances prevailing as at the date of the Fairness Opinion and the conditions, prospects, financial and otherwise, of the Company and Aurinia, as applicable, as they are reflected in the information and documents reviewed by Evans and as they were presented to Evans. Subsequent developments may affect the Fairness Opinion. Evans has disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Fairness Opinion which may come or be brought to the attention of Evans after the date of the Fairness Opinion.

As described above, under the terms of the engagement with Evans, the Company has agreed to pay Evans a fee for rendering the Fairness Opinion, regardless of the conclusions reached therein and regardless of whether the Arrangement is consummated. In addition, the Company agreed to reimburse Evans for its reasonable out-of-pocket expenses in connection with the provision of its services and to indemnify Evans against certain liabilities that may arise out of Evans’s engagement.

Evans and its affiliates comprise a full service securities firm engaged in securities, commodities and derivatives trading, foreign exchange and other brokerage activities, and principal investing as well as providing investment banking, asset and investment management, financing and financial advisory services and other commercial services and products to a wide range of companies, governments and individuals. In the ordinary course of their businesses, Evans and its affiliates may invest on a principal basis or on behalf of customers or manage funds that invest, make or hold long or short positions, finance positions or trade or otherwise effect transactions in equity, debt or other securities or financial instruments (including derivatives, bank loans or other obligations) of the Company.

Steps in the Plan of Arrangement

Pursuant to the terms of the plan of arrangement (the “Plan of Arrangement”), commencing at the Effective Time, except as otherwise noted herein, the following shall occur without any further act or formality required on the part of any person (with the numbers subject to change depending on the total issued and outstanding Common Shares immediately prior to the Effective Time):

16

Table of Contents

The currently anticipated number of common shares of the Corporation issuable to ILJIN pursuant to the Transaction is 114,252,706 which, when combined with ILJIN’s current holdings of 28,444,444 common shares of the Corporation, totals 142,697,150 common shares of the Corporation, or 26.60% of the common shares of the Corporation, on a non-diluted basis following the Arrangement, assuming the maximum number of Common Shares are issued in the First Unit Offering and in the Arrangement (and prior to the issuance of up to 133,333,332 units of the Corporation to be issued in the Second Unit Offering). The only other securities of the Corporation issued to ILJIN in the past six months are the 4,444,444 Common Shares and 4,444,444 First Offering Warrants that were issued in the First Unit Offering on June 26, 2013. For a detailed listing of all of ILJIN’s Common Shares to be issued and issuable pursuant to the various transactions described in this Information Circular, see “The First Unit Offering – The Financing Structure”.

Following the receipt of the order of the Supreme Court of British Columbia (the “Court”) approving the Arrangement, as such order may be amended at any time prior to the Effective Date or, if appealed, then unless such appeal is withdrawn or denied, as affirmed or as amended on appeal (the “Court Order”) and prior to the Effective Date, the Company shall deliver or arrange to be delivered to the Depositary the Arrangement Consideration, including certificates representing the Shares required to be issued to ILJIN and former Aurinia shareholders in accordance with the Plan of Arrangement, which certificates shall be held by the Depositary as agent and nominee for ILJIN and such former Aurinia shareholders for distribution in accordance with the provisions of the Plan of Arrangement.

In connection with the Arrangement, the Company expects to issue a maximum of 300,000,000 Common Shares (including Common Shares issuable upon the due exercise of Replacement Warrants), based on the number of Aurinia Shares outstanding as at July 19, 2013. The exact number of Replacement Warrants, Common Shares and Aurinia Shares to be issued in connection with the implementation of the Plan of Arrangement may vary from those described above, depending on the total number of Common Shares Issued and outstanding immediately prior to the Effective Time; however, in no case will more than 300,000,000 Common Shares be Issued or issuable pursuant to the Arrangement (including Common Shares issuable upon exercise of the Replacement Warrants). The intended effect of the Arrangement is such that shareholders of Aurinia are to hold approximately 35% of the Common Shares upon completion of the Arrangement, ILJIN is to hold approximately 25% of the Common Shares upon completion of the Arrangement, and the current shareholders of the Company are to hold approximately 40% of the Common Shares upon completion of the Arrangement.

Risks associated with the Arrangement

There are risks associated with the Arrangement including: (i) the Company may not obtain the necessary approvals for completion of the Arrangement on satisfactory terms or at all; (ii) the Arrangement Agreement may be terminated in certain circumstances; (iii) the market reaction to the Arrangement and the future trading prices of the Shares cannot be predicted; (iv) there is uncertainty as to whether the Arrangement will have a positive impact on the business or share price of the Company.

The completion of the Arrangement is subject to a number of conditions precedent, certain of which are outside the control of the Company, including the receipt of the Court Order from the Court approving the Arrangement, and the receipt of all required material consents, waivers, permits orders and approvals. There can be no certainty and the Company can provide no assurance that these conditions will be satisfied or, if satisfied, when they will be satisfied.

Arrangement Agreement

A summary of the principal terms of the Arrangement Agreement is provided in this section. This summary does not purport to be complete and the final terms of the Arrangement Agreement may differ from the summarized herein. Any material amendments to the terms of the Arrangement Agreement will be announced by the Company in a press release in advance of the Meeting. The Arrangement Agreement contains covenants, representations and warranties of and from each of the Company, Aurinia and ILJIN and various conditions precedent, both mutual and with respect to each party to the Arrangement Agreement.

17

Table of Contents

Representations, Warranties and Covenants of the Company

The representations and warranties to be given by the Company are customary and appropriate for transactions of this nature in respect of matters pertaining to, among other things, the due execution and delivery of the Arrangement Agreement, constituting a binding obligation enforceable in accordance with its terms, its corporate existence and power, its authority to enter into and to perform its obligations under the Arrangement Agreement, the absence of any bankruptcy proceedings, the absence of litigation matters, its capitalization, its financial statements, its financial books, records and accounts, the absence of any subsidiaries, the non-violation of its constating documents, the non-violation of its contractual and other obligations in respect of its assets, the absence of material changes since December 31, 2012, convertible securities, the absence of any shareholders’ rights plan, its compliance with applicable laws, certain tax matters, the absence of any off-the-books accounts, the absence of any undisclosed liabilities, compliance with securities laws, its status as a reporting issuer, its insurance policies, its good and marketable title to or valid leasehold interest in all of its personal property, and brokerage or finder’s fees.

The Company covenants to, among other things, take all reasonable steps to obtain all necessary waivers, consents and approvals required to be obtained. The Company covenants and agrees to, among other things, apply for and use commercially reasonable efforts to obtain all regulatory approvals relating to the Company and fulfill all conditions to closing contained in the Arrangement Agreement applicable to the Company.

Representations, Warranties and Covenants of Aurinia

The representations and warranties to be given by Aurinia are customary and appropriate for transactions of this nature in respect of matters pertaining to, among other things, its corporate existence and power, certain of its subsidiaries, the due execution and delivery of the Arrangement Agreement, constituting a binding obligation enforceable in accordance with its terms, its authority to enter into and to perform its obligations under the Arrangement Agreement, the absence of any bankruptcy proceedings, the absence of litigation matters, its capitalization, its financial statements, its financial books, records and accounts, the non-violation of its constating documents, the non-violation of its contractual and other obligations in respect of its assets, the absence of material changes since December 31, 2012, convertible securities, the absence of any shareholders’ rights plan, its compliance with applicable laws, certain tax matters, the absence of any off-the-books accounts, the absence of any undisclosed liabilities, its insurance policies, its good and marketable title to or valid leasehold interest in all of its personal property, and brokerage or finder’s fees.

The Company covenants to, among other things, take all reasonable steps to obtain all necessary waivers, consents and approvals required to be obtained. The Company covenants and agrees to, among other things, apply for and use commercially reasonable efforts to obtain all regulatory approvals relating to the Company and fulfill all conditions to closing contained in the Arrangement Agreement applicable to the Company.

Representations, Warranties and Covenants of ILJIN

The representations and warranties to be given by ILJIN are appropriate and in-line with transactions of this nature in respect of matters pertaining to, among other things, its corporate existence and power, certain of its subsidiaries, the due execution and delivery of the Arrangement Agreement, constituting a binding obligation enforceable in accordance with its terms, its corporate existence and power, its authority to enter into and to perform its obligations under the Arrangement Agreement, the absence of any bankruptcy proceedings, and the absence of litigation matters.

The Company covenants to, among other things, take all reasonable steps to obtain all necessary waivers, consents and approvals required to be obtained. The Company covenants and agrees to, among other things, apply for and use commercially reasonable efforts to obtain all regulatory approvals relating to the Company and fulfill all conditions to closing contained in the Arrangement Agreement applicable to the Company.

Conditions

The obligations of the Company and Aurinia to consummate the Arrangement are subject to the satisfaction of certain mutual conditions relating to, among other things:

18

Table of Contents

The obligations of the Company to consummate the Arrangement are subject to the satisfaction of certain conditions relating to, among other things:

The obligations of Aurinia to consummate the Arrangement are subject to the satisfaction of certain conditions relating to, among other things:

The obligations of ILJIN to consummate the Arrangement are subject to the satisfaction of certain conditions relating to, among other things:

19

Table of Contents

Termination of Arrangement Agreement

The Arrangement Agreement may be terminated at any time prior to the Effective Time (notwithstanding approval of the Share Issuance Resolution by the Company shareholders or of the Arrangement by Aurinia’s shareholders in a number of circumstances, including:

If either the Company or Aurinia wishes to terminate the Arrangement Agreement (other than termination by mutual written agreement of the Company and Aurinia), it shall give notice of such termination to the other Party, specifying in reasonable detail the basis for such Party’s exercise of its termination right.

If the Arrangement Agreement is terminated, it shall become void and be of no further force or effect without liability of any Party (or any shareholder, director, officer, employee, agent, consultant or representative of such Party) to any other Party hereto, except that the provisions relating to termination, termination fees, notices and governing law and jurisdiction, and all related definitions, shall survive any termination of the Arrangement Agreement.

20

Table of Contents

Termination Fees

In the event that the Arrangement Agreement is terminated, no fees, expenses or other payments shall be payable by either Party to the other.

Approvals

Court Approval of the Arrangement

The Arrangement under the BCBCA requires the approval of the Court.

Although the authority of the Court is very broad under the BCBCA, the Company has been advised by counsel that the Court will consider, among other things, the fairness and reasonableness of the terms and conditions of the Arrangement to the Company Shareholders and the rights and interests of every person affected. The Court may approve the Arrangement as proposed or as amended in any manner as the Court may direct, subject to compliance with such terms and conditions, if any, as the Court deems fit. The Court Order is required for the Arrangement to become effective.

Company Shareholder Approval

The shareholders of the Company must pass the Share Issuance Resolution at the Meeting. The Share Issuance Resolution to be passed by the Company Shareholders authorizes the Board, without further notice or approval of the Company Shareholders to amend the Arrangement, to decide not to proceed with the Arrangement and to revoke said resolution at any time prior to the Arrangement becoming effective under the provisions of the BCBCA.

Aurinia Shareholder Approval

Under the requirements of the BCBCA, the shareholders of Aurinia must pass a resolution with respect to the Arrangement by at least 66 ²⁄₃% of the votes cast by Aurinia shareholders present in person or by proxy at a special meeting of the Aurinia shareholders. The special resolution to be passed by the Aurinia shareholders with respect to the Arrangement authorizes the Aurinia Board, without further notice or approval of the Aurinia shareholders to amend the Arrangement, to decide not to proceed with the Arrangement and to revoke said resolution at any time prior to the Arrangement becoming effective. It is expected that Aurinia Shareholders will pass a resolution in writing pursuant to which 100% of Aurinia’s Shareholders will approve the Arrangement.

Regulatory Approval

The Arrangement Agreement provides that receipt of all applicable regulatory approvals is a condition precedent to the Arrangement becoming effective. There is no guarantee that the requisite approvals will be granted on a timely basis or on conditions satisfactory to the Company or Aurinia.

About Aurinia

Corporate Structure

Aurinia is a company incorporated on April 3, 2012 under the Business Corporations Act (British Columbia), having a principal office at #1203 – 4464 Markham Street, Victoria, British Columbia, Canada. Aurinia has two wholly-owned subsidiaries, Aurinia Holdings Corp. and Aurinia Development Corp., each formed and existing under the laws of Barbados.

Aurinia’s Business

Aurinia’s business involves holding intellectual property rights in various medical technologies, including certain rights to the large Aspreva Lupus Management Study (developed by Aspreva, and which resulted in the emergence of mycophenolate mofetil as a new standard treatment for patients suffering from this devastating and potentially fatal disease) and the license for voclosporin in lupus nephritis.

21

Table of Contents

Aurinia has only been in operation since incorporation on April 3, 2012, and has developed its business in that time by acquiring the above intellectual property and negotiating the Arrangement Agreement. Additionally, Aurinia has achieved a number of significant milestones in relation to its development activities in lupus nephritis. An active Investigational New Drug application has been established with the United States Food and Drug Administration and clinical test batches of a unique dose of voclosporin has been established.

Aurinia’s Authorized Share Capital

The authorized share capital of Aurinia currently consists of an unlimited number of common shares, one Class A share and an unlimited number of preferred shares. As of the date of this Information Circular, there are 6,079,159 common shares, one Class A share and warrants to acquire 35,294 common shares of Aurinia outstanding.

Aurinia’s Directors

The table below sets out information with respect to Aurinia’s directors.

Aurinia’s Legal Proceedings

Aurinia is not party to any material legal proceedings, nor to the best of its knowledge are there any material proceedings threatened or pending.

Aurinia’s Material Contracts

Aurinia’s only material contract is the Settlement Agreement (and, once the Arrangement Agreement is finalized and executed, the Arrangement Agreement will be a material contract of Aurinia).

Aurinia’s Auditors

Aurinia’s auditor is KPMG LLP, who have been Aurinia’s auditors since incorporation. KPMG LLP’s office is in Victoria, British Columbia.

22

Table of Contents

Selected Financial Information of Aurinia

A summary of certain financial information with respect to Aurinia is set out in the table below. This information is derived from the audited financial statements of Aurinia, which are attached as Appendix E. The following information is subject to the full disclosure included in such financial statements.

At the Meeting, Shareholders will be asked to consider and, if thought advisable, pass a special resolution (the “Constating Document Amendment Resolution”) approving amendments to the Company’s constating documents to: (i) change the Company’s name from “Isotechnika Pharma Inc.” to “Aurinia Pharmaceuticals Inc.”; and (ii) to include an advance notice requirement in respect of director nominations in the Company’s constating documents.

Name Change

The Company is proposing to change its name from “Isotechnika Pharma Inc.” to “Aurinia Pharmaceuticals Inc.” in connection with the Arrangement. The name change is to reflect the change in the Company’s business and focus resulting from the acquisition of the assets of Aurinia and the intellectual property from ILJIN in the Arrangement, and to provide notice to the market of a new focus for the Company in the future. Management of the Company is of the view that the Arrangement is an opportune time to rebrand the Company and its business.

Advance Notice Clause

Management of the Company is always striving to be at the top of corporate governance practices. Accordingly, the Company is proposing to amend its articles to include a provision (the “Advance Notice Clause”) that requires that advance notice to the Company must be provided in circumstances where nominations of persons for election to the board of directors are made by shareholders of the Company other than pursuant to: (i) a “proposal” made in accordance with the Business Corporations Act (Alberta); or (ii) a requisition of the shareholders made in accordance with the Business Corporations Act (Alberta).

Among other things, the Advance Notice Clause fixes a deadline by which holders of record of common shares of the Company must submit director nominations to the secretary of the Company prior to any annual or special meeting of shareholders and sets forth the specific information that a shareholder must include in the written notice to the secretary of the Company for an effective nomination to occur. No person will be eligible for election as a director of the Company unless nominated in accordance with the provisions of the Advance Notice Clause.

In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 nor more than 65 days prior to the date of the annual meeting; provided, however, that in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.

In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.

The Advance Notice Clause is similar to clauses adopted by other public companies and in accordance with the recommendations made by proxy solicitation firms Institutional Shareholder Services Inc. and Glass Lewis, & Co., LLC.

Resolution

The full text of the proposed Constating Document Amendment Resolution is set out in Appendix C hereto. In addition, shareholders should be aware that even if they approve the Constating Document Amendment Resolution at the Meeting, the proposed form of the Constating Document Amendment Resolution provides the directors with the discretion not to proceed with the amendments to the articles in whole or in part if they determine that to be in the best interests of the Company.

23

Table of Contents

The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the approval of the Constating Document Amendment Resolution, unless otherwise directed by the shareholders appointing them.

The Board seeks shareholder approval to implement a consolidation (also known as a “reverse split”) of the outstanding Shares such that each 50 outstanding Common Shares will be consolidated into one Common Share (the “Consolidation”). In order to be implemented, the Consolidation must be approved by at least two-thirds of the votes cast at the Meeting. The Board previously passed a resolution to approve the Consolidation on June 6, 2013.

In addition to the issued and outstanding Common Shares, the Common Shares currently reserved for issuance by the Company, including those Common Shares reserved pursuant to outstanding stock options, will be adjusted to give effect to the Consolidation, such that the number of consolidated Common Shares issuable will equal the number obtained when the number of Common Shares issuable is divided by the conversion number and the exercise prices of outstanding stock options to purchase Common Shares post-Consolidation will equal the price obtained by multiplying the existing exercise price by the conversion number.

The primary purpose of completing the Consolidation is to increase the market price of the Common Shares. The directors believe that the higher share price that might initially result from the Consolidation could help generate interest in the Company among investors and thereby assist the Company in raising future capital to fund its operations or make acquisitions. Shareholders should be aware that the issuance in the future of additional authorized shares may have the effect of diluting the earnings per Common Share and book value per Common Share, as well as the stock ownership and voting rights, of the currently outstanding Common Shares.

Shareholders should note that the ultimate effect of the Consolidation upon the market price for the Common Shares cannot be accurately predicted. In particular, if the Consolidation is implemented, there is no assurance that the market price for Common Shares will be fifty times greater than the price for Common Shares immediately prior to the reverse split. Furthermore, even if the market price of the Common Shares is initially significantly higher after the Consolidation, there can be no assurance that the market price of the Common Shares will maintain such level for any period of time.

In addition, shareholders should be aware that even if they approve the Consolidation Resolution at the Meeting, the proposed form of the Consolidation Resolution provides the directors with the discretion not to proceed with the Consolidation if they determine that to be in the best interests of the Company.

Fractional Common Shares which would otherwise be issued to shareholders in connection with the Consolidation will be not be issued but will, instead, be rounded down to the next nearest whole number of Common Shares. If the Consolidation Resolution is approved at the Meeting and the directors decide to proceed with the Consolidation, the Company will send letters of transmittal to each registered shareholder providing instructions on how shareholders may obtain new certificates representing the number of Common Shares to which they are entitled as a result of the Consolidation.

The Company currently has no intention of going private, and the proposed Consolidation is not intended to be a first step in a going private transaction. In addition, the Consolidation will not have the effect of a going private transaction covered by Rule 13e-3 of the United States Securities Exchange Act of 1934, as amended.

The full text of the Consolidation Resolution is set out in Appendix C hereto.

The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the approval of the Share Consolidation Resolution, unless otherwise directed by the shareholders appointing them.

If the proposed resolution is passed at the Meeting and the Board determines to proceed with the Consolidation, the Company will announce that it is proceeding with the consolidation. Registered holders should then, at that time, complete, sign and return the Letter of Transmittal that will be sent to such registered holders, along with the share certificate(s) representing their

24

Table of Contents

pre-consolidation Common Shares, to Computershare Investor Services Inc. at one of the addresses in the Letter of Transmittal. Upon receipt of a properly-completed and signed Letter of Transmittal and the share certificate(s) referred to in the Letter of Transmittal, the Company will arrange to have a new share certificate representing the appropriate number of post-Consolidation Common Shares delivered in accordance with the instructions provided by the holder in the Letter of Transmittal. No delivery of a new certificate to a shareholder will be made until the shareholder has surrendered his current issued certificates. Until surrendered, each share certificate formerly representing old Common Shares shall be deemed for all purposes to represent the number of new Common Shares to which the holder is entitled as a result of the Consolidation.

If the Company does not proceed with the Consolidation within one year from the date it receives shareholder approval for the Consolidation, it will again seek shareholder approval before conducting a share consolidation.

In the event that the Arrangement closes, the Company has agreed with Aurinia and ILJIN to have members of their choosing nominated to the Company’s board of directors. Accordingly, shareholders are being asked to approve, on a conditional basis, an ordinary resolution setting the size of the board of directors at seven, and ordinary resolutions to elect the following individuals as directors of the Company. Each of these resolutions is conditional on the Arrangement closing.

The Board recommends that shareholders vote for the election of the nominees whose names are set forth below. The persons named in the enclosed form of proxy intend to cast the votes to which the Common Shares represented by such proxy are entitled FOR the election of the nominees whose names are set forth below, conditionally on the closing of the Arrangement, unless otherwise directed by the shareholders appointing them.

If elected and the Arrangement closes, each director elected will hold office until the next annual meeting of shareholders or until his successor is duly elected, unless his office is earlier vacated in accordance with the Bylaws of the Company. The election of each director set out below is conditional on the Common Shares being listed on a stock exchange at the effective time of the election of such director.

If these directors are not elected, or if the Arrangement does not close, the directors elected pursuant to the vote proposed earlier in this Information Circular shall retain their positions as directors of the Company.

The following table states the names of all of the persons proposed by management to be nominated for election as directors (conditional on the closing of the Arrangement), their municipality, province or state and country of residence, their age, their principal occupation, their position in the Company (if any), the period during which each proposed nominee has served as a director and the number of Common Shares beneficially owned, directly or indirectly, by each of them or over which they exercise control or direction.

25

Table of Contents

Notes:

Biographies for Peter Wjingaard, Robert Foster and Donald Wyatt are set out earlier in this information circular under “Election of Directors”. The following are brief biographies for each of the other persons conditionally nominated for election as directors:

Daniel Park

Mr. Park is currently the Executive Vice-President of ILJIN Group. He started his management career with ETEX Corp, an advanced biomaterials company focusing on products that promote bone repair and enable controlled delivery therapies in 1988. ETEX is one of the subsidiaries of ILJIN Group, and Mr. Park has since worked in numerous ILJIN Group companies including ILJIN Display Co., Ltd. and ILJIN Diamond Co., Ltd. in senior management positions. He is presently in the Planning Office of ILJIN Group which contains multiple sub companies ranging from the Jeonju Television Co., Ltd. to ILJIN Electricity Co., Ltd.

Mr. Park holds Masters of Business Administration (University of California at Los Angeles), along with a Masters and a Bachelor’s degree in Economics from Seoul National University.

Richard Glickman

Richard M. Glickman was Co-founder, Chairman and Chief Executive Officer of Aspreva Pharmaceuticals Corporation (“Aspreva”) between January 2002 and July 2007. Dr. Glickman also served as the Chief Executive Officer for StressGen Biotechnologies Corp from 1990 until 2000. Dr. Glickman sits on a variety of private and public boards and has served on numerous compensation committees. Dr. Glickman has participated in the design, establishment, and implementation of executive compensation and benefit programs and also participated in, and overseen, the design, establishment and implementation of compensation and benefit programs for non-executive employees. In Dr. Glickman’s executive leadership roles, the Vice-President of Human Resources reported to him. He also has direct experience in performance management of

26

Table of Contents

executive, senior level and rank-and-file employees in small and larger organizations. In his role as a manager and motivator of people, he has experience in establishing, monitoring and evaluating strategic and annual personnel and group performance objectives.

Michael Martin

Mr. Martin is currently Chief Operating Officer & Co-founder of Aurinia. In this role, Mr. Martin is responsible for managing company functions such as corporate and business development, alliance management, marketing, finance and internal company operations. Mr. Martin is a biotech/pharmaceutical executive with over 17 years industry experience and offers a solid mix of strategic planning, marketing, commercial operations, business development, licensing and people management skills.

Mr. Martin joined Aurinia from Aspreva where he held the position of Director, Global Business Development & Licensing. Prior to Aspreva, Mr. Martin was a key member of the business development team that saw Aspreva sold to Galenica for $915M. Upon joining Aspreva in 2004, Mr. Martin initiated the strategic launch planning process for CellCept^® in “less-common” autoimmune diseases. These included such indications as Pemphigus Vulgaris, Myasthenia Gravis, and Lupus Nephritis. Prior thereto, Mr. Martin held a variety of progressively senior commercial positions at Schering-Plough. Most recently, Mr. Martin has spent time in Europe where he was responsible for the Rheumatology business unit for Remicade^® in France. There, Mr. Martin had full profit and loss responsibilities and had direct responsibility for the sales team, the marketing team and the infusion access team. In addition while at Schering-Plough, Mr. Martin was the brand manager responsible for the Canadian launch of Remicade (infliximab), which ultimately became the most successful product launch in Canadian history. Mr. Martin started his career in the industry in the sales organization of Schering-Plough where he received multiple awards and recognition while rapidly progressing towards the prior mentioned roles.

Chris Kim

Dr. Kim is currently CEO, Lumirich Co., and Iljin Semicon Co., of Seoul, Korea dating from 2008 to present. Prior to that, from 2006 to 2008, Dr. Kim was CEO, Iljin Display Co., Korea. From 2000 to 2006, Dr. Kim was Vice-president, Sales and Marketing at Samsung SDI Co, Korea, where he was in charge of Samsung SDI’s worldwide plasma display panel sales and marketing. During his tenure with Samsung SDI Co., Dr. Kim gained considerable commercial experience with CE related products to OEM customers including, for example, Philips Consumer Electronics, Sony, Dell, and Hewlett-Packard. From 2001 to 2005, Dr. Kim was able to increase revenue growth from approximately $0.7 million to $1.7 billion. Dr. Kim had increasing responsibilities from 1986 to 1999 while at companies including NSF Polymer Research Center, VPI, in Blacksburg, Virginia, USA; Exxon-Mobil Corp., in Rochester, NY, USA; Corning Inc., in Corning, NY, USA; Lam Research Corp., in Fremont, California, USA, and Fujitsu Inc., in San Jose, California, USA. Dr. Kim has an undergraduate Science degree in Chemical Engineering from Seoul National University (1985) and a PhD in Chemical Engineering (1989) from Virginia Tech., Blacksburg, Virginia, USA. He also has more than ten technical publications, one book chapter, and numerous worldwide patents, and is fluent in three languages.

Corporate Cease Trade Orders, Bankruptcies, Penalties or Sanctions

To the knowledge of the directors and officers of the Company, no proposed director of the Company:

27

Table of Contents

PART 3

STATEMENT OF EXECUTIVE AND DIRECTOR COMPENSATION

The following compensation discussion and analysis provides information regarding all significant elements of compensation paid, awarded or otherwise provided by the Company to its Named Executive Officers (defined below). Specific information is provided for Robert Foster, Chief Executive Officer, Dennis Bourgeault, Chief Financial Officer, and the three other most highly compensated executive officers of the Company whose total compensation for the year ended December 31, 2012, individually, was more than CDN$150,000: namely, Launa Aspeslet, Chief Operating Officer, Derrick Freitag, Chief Scientific Officer, and Robert Huizinga, Vice President, Clinical Affairs (collectively, the “Named Executive Officers” or the “NEOs”). Information about the compensation awarded to the Named Executive Officers can be found in the “Summary Compensation Table” and related compensation tables below.

This Section of the Circular explains how the executive compensation program is designed with respect to the CEO and the other Named Executive Officers. In designing the compensation program the Board has several key objectives:

The Compensation, Corporate Governance and Nominating Committee currently is comprised of three (3) independent Directors: Donald W. Wyatt, who serves as the Chair, Dr. Peter Wijngaard, and Prakash Gowd. No member of the committee is an officer or employee of the Company.

Annually, specific and measurable performance objectives are defined for each Executive. The objectives against which the Executives were evaluated include research and product development goals/milestones, execution of development and commercialization agreements, organizational development objectives and financial targets.

On an annual basis, or otherwise more frequently as circumstances require, the Compensation, Corporate Governance and Nominating Committee considers whether the executive compensation programs create or incentivize any inappropriate risk-taking. It is important to undertake such an analysis because it is expected that going forward annual performance-based incentives will continue to play a primary role in Named Executive Officers’ and other senior management’s compensation programs. Therefore, the Company must ensure that these incentives do not result in actions being taken that are not in the long-term interest of the Company. Compensation plans and programs for 2012 considered both short-term incentives and long-term incentives for Named Executive Officers and other senior managers to enhance the balance between risk and reward in relation to the Company’s overall business strategy and to further discourage the taking of unnecessary or excessive risks.

The contractual base salaries of all Named Executive Officers in 2012 were the same as the base salaries for 2011.

28

Table of Contents

Effective for the period August 16, 2012 to December 31, 2012, the NEOs voluntarily reduced their salaries to 70% of their contractual base salaries.

In determining executive compensation, the Company previously, in 2009, undertook a review of several sources of comparator data including an internal review of small cap public Canadian Biotechnology companies.

Salary levels were based on the experience and expertise of each executive. In reference to the benchmarking analysis that was conducted by the Board in June of 2009 the goal was to place the executives in the 50% to 75% percentile.

At the July 28, 2011 Board meeting, the Chair of the Compensation, Corporate Governance and Nominating Committee recommended and the Board agreed with the specific bonus objectives for 2011 and 2012 for each of the Named Executive Officers.

The following bonuses were earned upon the achievement of specific milestones in 2012: Chief Executive Officer - $9,000; Chief Financial Officer - $3,000; Chief Operating Officer - $6,000; Chief Scientific Officer - $3,375; Vice President, Clinical Affairs - $3,426.

The following bonuses were earned upon the achievement of specific milestones in 2011: Chief Executive Officer - $27,000; Chief Financial Officer - $6,000; Chief Operating Officer - $12,000; Chief Scientific Officer - $6,750; Vice President, Clinical Affairs - $5,138. These bonuses were accrued in 2011 but paid in the first quarter of 2012 and therefore are included in the Summary Compensation Table under section 3.1.4 for 2012.

In 2012 the Chair of the Compensation, Corporate Governance and Nominating Committee recommended and the Board approved the implementation of a long term retention incentive for the CEO and the NEOs, particulars of which are as follows:

The CEO will receive 2% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.3% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company, provided that: (1) he is serving as CEO at the time the license under which the royalties are paid was executed; and (2) he is serving as CEO at the time the first royalty is paid by the licensee in question or, in the case of direct sales by the Company, at the time of the first direct commercial sale of voclosporin by the Company.

Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger in a manner such that this payment obligation is no longer operative, then he will be entitled to receive 0.3% of the value attributable to voclosporin in the transaction, provided that he is serving as CEO of the Company at the time of the transaction.

Should the CEO’s employment be terminated without just and sufficient “Cause” or if the CEO terminates his employment for “Good Reason”, as those terms are defined in his Employment Agreement, or if his employment is not renewed by the Company as set forth in his Employment Agreement, conditions (1) and (2) above shall not apply and the CEO will be entitled to receive the royalty licensing revenues he would have been entitled to receive had his employment not been terminated.

The currently serving four NEOs (namely Dennis Bourgeault, Launa Aspeslet, Derrick Freitag and Robert Huizinga) and excluding the CEO, shall each receive 0.1675% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.025% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company, provided that the NEO in question is employed by or a consultant to the Company or one of its subsidiaries at the time such amount is payable. Should an NEO cease to be employed by or cease to be a consultant to the Company or one of its subsidiaries, payment obligation to that NEO shall cease.

Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger in a manner such that this payment obligation is no longer operative, then those NEOs will be entitled to receive 0.025% of the value attributable to voclosporin in the transaction, provided that he or she is serving as an Executive Officer of the Company at the time of the transaction.

29

Table of Contents

Should an NEO’s employment be terminated without just and sufficient “Cause” as set forth in his or her Employment Agreement, the NEO will be entitled to receive the royalty licensing revenues he or she would have been entitled to receive had his or her employment not been terminated.

The Company has a stock option plan which it believes helps align management interests with shareholders’ interests. In 2012, option grants to the Named Executive Officers were time release grants with one-third vesting on December 31, 2012, one-third vesting on May 31, 2013 and the remaining one-third vesting on November 30, 2013.

Base Salary

A function of the Compensation, Corporate Governance and Nominating Committee is to monitor and assess Dr. Robert Foster’s performance and to recommend his compensation to the Board for approval. The Board supports the principle that CEO compensation should be directly related to the overall current performance of the Company and its potential for continued future growth. As such, in determining recommendations for Dr. Foster’s total compensation, the Compensation, Corporate Governance and Nominating Committee considered:

Accordingly, the Compensation, Corporate Governance and Nominating Committee reviews this information, as well as the performance of the Company and of the Chief Executive Officer individually when recommending the Chief Executive Officer’s salary and annual incentives for a given year.

Bonus

The Chief Executive Officer is compensated using the same plan as described above for Named Executive Officers with the exception that the Chief Executive Officer was eligible for a bonus based upon 30% of base salary versus from 11.25% to 15% for the Company’s other Named Executive Officers.

Option-based Awards

The options granted to the Chief Executive Officer in the 2012 financial year pursuant to the Stock Option Plan were granted on the same basis and pursuant to the same terms as those of the other Named Executive Officers. The number of options granted was determined on the basis of his position and base salary for 2012, taking into consideration the terms of the Stock Option Plan discussed above. The granted options were time release grants with one-third vesting on December 31, 2012, one-third vesting on May 31, 2013 and the remaining one-third vesting on November 30, 2013.

Revised CEO Compensation

In early 2012 Hay Group Limited was retained by the Company to review the market competitiveness of the Company’s CEO compensation structure. Working together, Hay Group and the Company established three (3) potential comparator groups. From a high level perspective, comparator organizations were chosen based on the following criteria:

30

Table of Contents

The Hay Group positioned the Company in the 50^th percentile. Upon receipt of the Hay Group market compensation review, the Compensation, Corporate Governance and Nominating Committee recommended to the Board that the Company enter into a new employment agreement with Dr. Foster which provided for a base salary of $385,000 plus additional bonuses and stock option grants to be determined annually by the Compensation, Corporate Governance and Nominating Committee. The Board subsequently approved the employment agreement with Dr. Foster on March 8, 2012.

Effective August 16, 2012 to December 31, 2012, the CEO voluntarily reduced his salary to 70% of his contractual base salary.

The Company’s Common Shares are listed and posted for trading on the TSX under the trading symbol “ISA”. The following graph and table compare the cumulative total return on the Company’s Common Shares (assuming a $100 investment was made on December 31, 2007 and assuming the reinvestment of dividends) with the cumulative total return of the S&P/TSX Composite Index, and the S & P/TSX Capped Health Care for the period which commenced on December 31, 2007 and ended on December 31, 2012.

The trend shown in the graph above does not necessarily correspond to the Company’s compensation to the executive officers for the periods represented in the graph. Due to the volatile nature of the public markets for pharmaceutical companies such as the Company in recent years, it is difficult to rationalize corporate performance, including individual executive officer performance, to the Company’s stock price performance. None of the executive officer’s compensation is directly dependent on stock performance. The number of options issued under the Current Stock Option Plans is indirectly affected by stock performance in that the stock price is considered when determining the number of options to be issued.

As of December 31, 2012, the Company did not have a formal policy specifically prohibiting a director or NEO from purchasing financial instruments designed to hedge or offset a decrease in market value of any Common Shares granted as compensation or

31

Table of Contents

held, directly or indirectly, by the NEO or director. The Company has adopted a written code of business conduct (the “Code”) for its directors, officers and employees, which is filed on SEDAR at www.sedar.com under the Company’s profile. The Code requires that all employees act at all times in full compliance with all laws applicable to the business of the Company. The Board implemented a written anti-hedging policy for all employees, directors and senior officers of the Company on March 8, 2012.

The following table details the compensation information for each of the Company’s three most recently completed financial years for the Named Executive Officers.

Notes:

The Company based its determination of expected volatility on the historical market volatility of its shares.

32

Table of Contents

The following is a summary of the management contracts for each of the executive officers of the Company:

Dr. Robert Foster

On March 9, 2012 Dr. Foster entered into a new employment agreement with the Company for a term ending on December 31, 2015 respecting his employment as the Chief Executive Officer and as a director of the Company, replacing the previous employment agreement entered into on January 1, 2006, as amended on April 30, 2008, which agreement had expired December 31, 2009. Dr. Foster had no formal employment agreement from January 1, 2010 to March 8, 2012. The new agreement provides that Dr. Foster will devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis. In addition to base salary, Dr. Foster is entitled to participate in the Company’s benefits program and is eligible to receive a cash bonus and option bonus based upon the achievement of certain performance goals as the Board of Directors may establish from time to time and ratified by the Board for each calendar year in accordance with the Bonus Plan. Dr. Foster is also entitled to receive a retention incentive as described in 3.1.2(c)(i) above, subject to the conditions therein described.

Dr. Launa Aspeslet, Dennis Bourgeault and Dr. Derrick Freitag

Each of the named individuals entered into a new employment agreement for an indeterminate term, effective June 19, 2009, respecting their employment as an executive of the Company, replacing the previous employment contracts entered into on January 1, 2006, as amended on April 30, 2008. The agreement provides that the Executive shall devote his (her) sole skill and efforts to discharging his (her) duties to the Company on a full-time and exclusive basis. In addition to base salary, each of the named individuals is entitled to participate in the Company’s benefits program and is eligible to receive a cash bonus and option bonus based upon the achievement of certain performance goals as the Board of Directors may establish from time to time and ratified by the Board for each calendar year in accordance with the Bonus Plan. Each of the named individuals is also entitled to receive a retention incentive as described in 3.1.2(c)(ii) above, subject to the conditions therein described. Each of these named individuals agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.

Robert Huizinga

Robert Huizinga entered into an employment agreement for an indeterminate term, effective January 1, 2012, respecting his employment as an executive of the Company. The agreement provides that the Executive shall devote his sole skill and efforts to discharging his duties to the Company on a full-time and exclusive basis. In addition to base salary, he is entitled to participate in the Company’s benefits program and is eligible to receive a cash bonus and option bonus based upon the achievement of certain performance goals as the Board of Directors may establish from time to time and ratified by the Board for each calendar year in accordance with the Bonus Plan. Mr. Huizinga is also entitled to receive a retention incentive as described in 3.1.2(c)(ii) above, subject to the conditions therein described. Mr. Huizinga agreed to non-competition, non-solicitation, non-disclosure and assignment of intellectual property provisions in favour of the Company.

The following table indicates for each of the Named Executive Officers all awards outstanding at the end of the 2012 financial year.

33

Table of Contents

Notes:

34

Table of Contents

The following table indicates for each of the Named Executive Officers the value on vesting of all awards during the 2012 financial year.

Note:

Pursuant to the new employment agreement dated March 9, 2012 between the Company and Dr. Foster, termination and change of control benefits are as follows:

(i) In the event that Dr. Foster’s employment is terminated by the Company without just and sufficient cause, or if Dr. Foster terminates his employment for “Good Reason”, Dr. Foster is entitled to receive a cash payment in an amount (in addition to salary, benefits or other sums due to him through the termination date) equal to two times his annualized base salary then in effect. All of Dr. Foster’s unexercised stock options, including options based on the achievement of certain performance criteria, whether or not actually achieved, would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms. Assuming termination on December 31, 2012 and based on the compensation payable pursuant to his new employment agreement, a lump sum payment of $770,000, plus any benefits or other sums due to him through the termination date, would have been made to Dr. Foster. No additional amounts would have been realized by Dr. Foster on the exercise of stock options as there were no in-the-money options as at December 31, 2012.

(ii) In the event that Dr. Foster’s employment is terminated by the Company or by the Executive for “Good Reason” following a change in control of the Company, Dr. Foster is entitled to receive a cash payment in an amount (in addition to salary, bonuses and benefits then due him) equal to two times his annualized base salary then in effect. All of Dr. Foster’s unexercised stock options, with the exception of options based on the achievement of certain performance criteria, would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his stock options in accordance with their terms. Assuming termination on December 31, 2012 and based on the compensation payable pursuant to his new employment agreement, a lump sum payment of $770,000, plus bonuses and benefits then due him, would have been made to Dr. Foster. No additional amounts would have been realized Dr. Foster on the exercise of stock options as there were no in-the-money options as at December 31, 2012.

(iii) In the event that employment is terminated as a result of the death or permanent disability of Dr. Foster, Dr. Foster or his estate or legal representative would not be entitled to receive any additional compensation other than the salary, bonus, benefits, or other sums due up to and including the termination date. All stock options, including options based on the achievement of certain performance criteria, whether or not actually achieved, would fully vest and be exercisable over a period of one year from the date of termination.

35

Table of Contents

In the event that employment of these Named Executive Officers is terminated (i) by the Company without just and sufficient cause; (ii) by the Executive for “Good Reason”; or (iii) by the Company or by the Executive for “Good Reason” following a change in control of the Company, each of Dr. Launa Aspeslet, Dennis Bourgeault, Dr. Derrick Freitag and Robert Huizinga is entitled to receive a cash payment in an amount equal to one month of the Executive’s base salary then in effect per year of service to a maximum of 18 months, any Bonus earned by the Executive as of the termination date and the cash value of benefits and perquisites provided to the Executive with respect to the immediately preceding fiscal year. In the case of (i) or (ii) above, all of their unexercised stock options, including options based on the achievement of certain performance criteria, whether or not actually achieved, would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his/her stock options in accordance with their terms. In the case of (iii) above, all of their unexercised stock options, with the exception of options based on the achievement of certain performance criteria, would fully vest and would be exercisable over a period of 90 days pursuant to the terms and conditions under which the stock options were granted, subject to the prior expiry of his/her stock options in accordance with their terms.

Assuming termination on December 31, 2012, lump sum payments as follows would have been made to each of Dr. Launa Aspeslet, Dennis Bourgeault, Dr. Derrick Freitag and Robert Huizinga:

Note:

In the event that employment is terminated as a result of the death or permanent disability of the Named Executive Officers, the Executive or his/her estate or legal representative would not be entitled to receive any additional compensation other than the salary, bonus, benefits, or other sums due up to and including the termination date. All stock options, including options based on the achievement of certain performance criteria, whether or not actually achieved, would fully vest and be exercisable over a period of one year from the date of termination.

During the 2012 financial year, Directors were remunerated for services in that capacity with cash compensation, options to acquire Common Shares and a retention incentive plan bonus.

As at December 31, 2012, the Company’s Board of Directors consisted of three non-executive directors (Messrs. Gowd, Wijngaard and Wyatt) and Dr. Robert Foster, the Chief Executive Officer of the Company. Effective January 1, 2012, standard compensation for each non-executive directors consisted of: (i) an annual retainer of $10,000, paid quarterly; (ii) $1,000 for each Board or committee meeting attended in person (where committee meetings are held in conjunction with the Board meeting only one fee is paid); (iii) $500 for each Board or committee meeting attended by way of teleconference, to a maximum of five (5) Board meetings plus two (2) committee meetings per committee per quarter. The Chairman of the Board is entitled to receive an additional annual retainer of $40,000, paid quarterly, and the Chairs of the Audit and Compensation, Corporate Governance and Nominating Committees were each entitled to receive an additional annual retainer of $40,000, paid quarterly. The Company paid a total of $175,500 to the non-executive directors in retainer and meeting fees in 2012. In addition, stock options were granted to the non-executive directors on August 17, 2012 and December 11, 2012. The members of the Board were also eligible for reimbursement of their expenses incurred in connection with attendance at Board meetings. Dr. Foster did not receive separate compensation for acting as a company Director.

In 2012 the Chair of the Compensation, Corporate Governance and Nominating Committee recommended and the Board agreed to implement a long term retention incentive for the Board of Directors, such that each of Messrs. Gowd, Wijngaard and Wyatt shall receive 0.22% of royalty licensing revenue for royalties received on the sale of voclosporin by licensees and/or 0.033% of net sales of voclosporin sold directly by the Company, to be paid quarterly as that revenue is received by the Company, provided

36

Table of Contents

that the Director in question is serving as a director, employee or a consultant to the Company or one of its subsidiaries at the time such amount is payable. Should a Director cease to be a director of the Company or one of its subsidiaries in the manner set forth above, payment obligation to that Director shall cease.

Should the Company sell substantially all of the assets of voclosporin to a third party or transfer those assets to another party in a merger in a manner such that this payment obligation is no longer operative, then those Directors shall be entitled to receive 0.033% of the value attributable to voclosporin in the transaction, provided that the Director in question is serving as a director, employee or consultant to the Company or one of its subsidiaries at the time of the transaction.

Summary Compensation Table:

The following table provides details of the compensation awarded to, earned by, paid to or payable to the non-executive directors of the Company during the 2012 financial year.

Notes:

The Company based its determination of expected volatility on the historical market volatility of its shares.

Outstanding Share-Based Awards and Option-Based Awards

The following table indicates for each of the non-executive directors of the Company all awards outstanding at the end of the 2012 financial year:

37

Table of Contents

Note:

Value Vested or Earned on Incentive Plan Awards During the Most Recently Completed Fiscal Year:

The following table indicates for each of the non-executive directors of the Company the value on vesting of all awards during the 2012 financial year.

The shareholders approved the Stock Option Plan at the June 28, 2012 annual meeting. The following is a summary of the material terms of the Stock Option Plan:

38

Table of Contents

39

Table of Contents

The Company does not provide retirement benefits for directors or officers.

The following table indicates the number of Common Shares to be issued upon the exercise of outstanding options, the weighted average exercise price of such outstanding options and the number of Common Shares remaining for future issuance under the Stock Option Plan as at December 31, 2012.

Note:

No officers, directors, employees or former officers, directors and employees of the Company were indebted to the Company as at December 31, 2012.

PART 4

REPORT ON CORPORATE GOVERNANCE AND OTHER ITEMS

“Corporate governance” is the process and structure used to direct and manage the business and affairs of the Company to achieve the shareholders’ objectives. The CSA has adopted National Policy 58-201 – “Corporate Governance Guidelines” (the “Guidelines”) to provide guidance to Canadian reporting issuers regarding corporate governance. The Guidelines relate to a number of significant governance issues, including the proper role of the board of directors, its structure and composition and its relationship with shareholders and management. The CSA has also adopted National Instrument 58-101 – “Disclosure of Corporate Governance Practices” requiring that disclosure be made by a listed corporation of its corporate governance practices. A complete description of the Company’s corporate governance practices, with specific references to each of the Guidelines, is attached hereto as Appendix “B”. The Compensation, Corporate Governance and Nominating Committee, currently composed of Donald W. Wyatt, Peter Wijngaard and Prakash Gowd, has reviewed the disclosure set out in Appendix “B”.

The Compensation, Corporate Governance and Nominating Committee continues to periodically review corporate governance proposals made by the CSA. As new standards become effective, the Compensation, Corporate Governance and Nominating Committee will review and amend, where necessary and appropriate, its corporate governance practices and eligibility of the members of the Board on each committee and shall, if necessary, make appropriate changes.

40

Table of Contents

The Board has two (2) standing Committees: the Audit Committee and the Compensation, Corporate Governance & Nominating Committee.

The following are descriptions of the two standing Committees of the Board:

Audit Committee

Members: Prakash Gowd (Chair), Dr. Peter Wijngaard and Donald W. Wyatt

The Audit Committee is composed of three (3) independent directors, all of whom are “financially literate” as that term is defined in National Instrument 52-110 – Audit Committees (“NI 52-110”). Please refer to the description of the Audit Committee set out in the Company’s Annual Information Form for the year ended December 31, 2012 (the “AIF”), including the information required to be disclosed under NI 52-110, available on the SEDAR website at www.sedar.com.

Compensation, Corporate Governance and Nominating Committee

Members: Donald W. Wyatt (Chair), Dr. Peter Wijngaard and Prakash Gowd

The Compensation, Corporate Governance and Nominating Committee is composed of three (3) independent directors. The Committee is responsible for:

In addition, the Committee will review and/or approve any other matter specifically delegated to the Committee by the Board and undertake on behalf of the Board such other governance initiatives as may be necessary or desirable to enable the Board to provide effective governance for the Company and contribute to the success of the Company.

Communications, Insider Trading, Confidential Information and Disclosure Policies

The Board is committed to an effective communications policy with all stakeholders including shareholders, suppliers, advertisers, employees, agents and members of the investment community. The Company is committed to complying with all laws, regulations and policies which are applicable to it, as well as to best practices in the field. This commitment is evidenced, notably, by the adoption by the Company of a Corporate Disclosure Policy, Fraud Policy and Insider Trading Policy.

The Audit Committee or the Board reviews in advance all press releases which disclose financial results. Other continuous disclosure documents, including, without limitation, proxy materials and the AIF are reviewed by the Executive team and, where appropriate, the Board and, where required, these documents are also approved by the Board.

This section includes a description of the material interest, direct or indirect, of directors or executive officers of the Company, persons or companies that beneficially own, control, or direct more than 10% of the voting securities of the Company, or an associate or affiliate of any of such directors, executive officers, persons or companies, in the transactions conducted by the Company within the three most recently completed financial years or during the current financial year that has materially affected or is reasonably expected to materially affect the Company.

The Company and ILJIN entered into a Development, Distribution and License Agreement dated effective January 28, 2011 (the “DDLA”), for the further clinical and commercial development of voclosporin for use in transplant indications applicable to voclosporin. Mr. Chin-Kyu Huh was elected a Director of the Company on December 15, 2010 at a special meeting of the shareholders of the Company. Mr Huh was appointed Chairman of the Board on March 18, 2011 and resigned as Director and Board member on July 28, 2011. As a result of completing this transaction, ILJIN currently owns 24,000,000 shares of the Company, of which Mr. Huh is the beneficial owner as he owns 100% of ILJIN. The Company exercised its right to terminate the DDLA on January 30, 2012. For further information please refer to the AIF.

41

Table of Contents

Shareholders who comply with the applicable provisions of the ABCA are, subject to certain conditions in the ABCA, entitled to have the Company include in its management proxy circular any matter that the person proposes to raise at an annual meeting. Any shareholder who intends to make such a proposal to be considered by the Company for the Meeting must arrange for the Company to receive the proposal at its head office (5120 – 75 Edmonton, Alberta T6E 6W2) no later than April 16, 2014.

Financial information is provided in the Company’s audited financial statements and management’s discussion and analysis for its most recently completed financial year. Copies of these documents and additional information relating to the Company are available on the Company’s website www.isotechnika.com or on SEDAR at www.sedar.com.

To the knowledge of the Company, Evans and its designated professionals (as that term is defined in National Instrument 51-102) owns, as a group, directly or indirectly, less than 1% of the outstanding Common Shares.

The auditors of Aurinia are KPMG LLP, Chartered Accountants, who have prepared an independent auditors’ report dated May 30, 2013 in respect of Aurinia’s audited financial statements for the period from incorporation on April 3, 2012 to December 31, 2012. KPMG LLP is independent of Aurinia within the Rules of Professional Conduct of the Institute of Chartered Accountants of British Columbia.

The contents of this proxy circular and the sending thereof have been approved by resolution of the Board of Directors of the Company.

DATED at Edmonton, Alberta, July 19, 2013.

ON BEHALF OF THE BOARD OF DIRECTORS OF ISOTECHNIKA PHARMA INC.

42

Table of Contents

APPENDIX “A”

STATEMENT OF CORPORATE GOVERNANCE PRACTICES

The Company is committed to the highest standards of corporate governance. The Board and each of its committees have continued to refine the Company’s governance policies and procedures in light of recent regulatory initiatives that have been adopted to improve corporate governance.

Effective June 30, 2005 National Instrument 58-101 Disclosure of Corporate Governance Practices (“NI 58-101”) and National Policy 58-201 Corporate Governance Guidelines (“NP 58-201”) were adopted in Canada. NI 58-101 requires issuers to disclose the corporate governance practices that they have adopted. NP 58-201 provides guidance on corporate governance practices. In addition, the Company is subject to NI 52-110, which has been adopted in various Canadian provinces and territories and which prescribes certain requirements in relation to audit committees.

The Board will continue to review the Company’s corporate governance practices on an ongoing basis in response to the evolving regulatory standards.

A-1

Table of Contents

A-2

Table of Contents

A-3

Table of Contents

A-4

Table of Contents

A-5

Table of Contents

A-6

Table of Contents

APPENDIX “B”

MANDATE OF THE BOARD OF DIRECTORS

Introduction

The primary responsibility of the board of directors (“Board”) of Isotechnika Pharma Inc. (the “Company”) is to oversee the management of the business and to pursue the best interests of the Company. The Board has plenary power and exercises overall responsibility for the management and supervision of the affairs of the Company.

Board Size and Criteria

Pursuant to the Articles of the Company, the Board must consist of at least one (1) director and not more than twenty (20) directors. The By-laws of the Company require that at least one-quarter (1/4) of the Company’s directors be resident Canadians, and that at least two (2) of the Company’s directors must not be officers or employees of the Company or a subsidiary of the Company. A majority of the directors of the Board shall be independent within the meaning of National Instrument 52-110 Audit Committees.

Board Meetings

In order for the Board to transact business, a majority of the directors must be present. The Board shall meet on a regular basis and shall schedule a sufficient number of meetings (whether in person or by teleconference) to carry out its mandate, which shall occur at least once each quarter.

Reports From Committees/Subsidiaries

Unless waived by the Board, each committee chair shall provide a report to the Board on material matters considered by the committee at the first Board meeting after the committee’s meeting. Each board of a material subsidiary that does not have the same directors as the Board shall provide a report to the Board on material matters considered by the subsidiary board at the first Board meeting after the subsidiary’s meeting.

Chairman

The Board shall appoint a Chairman of the Board who shall have responsibility to ensure that the Board discharges its duties and responsibilities.

Outside Advisors

The Board shall have the authority to retain, at the Company’s expense, independent advisors and consultants to advise the Board as it determines necessary to carry out its duties and to fix the remuneration of such advisors and consultants. The Board may request any officer or employee of the Company, or the Company’s internal or external auditors or legal counsel to attend a meeting of the Board or to meet with any directors of, or consultants to, the Board.

Governance

The Board has responsibility for developing the Company’s approach to governance issues although the Governance Committee plays a key role by recommending and reporting on governance issues, including ethical conduct, to the Board. The Board may delegate specific governance issues to other committees of the Board. The Board is responsible for establishing the appropriate procedures to ensure that the Board, Board committees and individual directors can function independently of management.

General Duties

It is the duty of the directors of the Company to manage, or supervise the management of, the business and affairs of the Company. In exercising his or her duties, every director shall act honestly and in good faith with a view to the best interests of the Company and exercise the care, diligence and skill that a reasonably prudent person would exercise in similar circumstances. Each director shall also comply with the provisions of the Business Corporations Act (Alberta), and the By-laws of the Company.

Directors’ Duties and Responsibilities

The Board has responsibility for stewardship of the Company, including:

B-1